Hydroxychloroquine in a G6PD-Deficient Patient with COVID-19 Complicated by Haemolytic Anaemia: Culprit or Innocent Bystander?

Mastroianni, François; Colombie, Vincent; Claes, Geraldine; Gilles, Axelle; Vandergheynst, Frédéric; Place, Sammy

Mastroianni, François; Colombie, Vincent; Claes, Geraldine; Gilles, Axelle; Vandergheynst, Frédéric; Place, Sammy.

Mastroianni F; Department of Internal Medicine, EpiCURA Hospital, Hornu, Belgium.
Colombie V; Department of Internal Medicine, EpiCURA Hospital, Hornu, Belgium.
Claes G; Department of Haematology, EpiCURA Hospital, Hornu, Belgium.
Gilles A; Department of Haematology, EpiCURA Hospital, Hornu, Belgium.
Vandergheynst F; Department of Internal Medicine, Erasme Hospital, Brussels, Belgium.
Place S; Department of Internal Medicine, EpiCURA Hospital, Hornu, Belgium.

Eur J Case Rep Intern Med ; 7(9): 001875, 2020.

Article in English | MEDLINE | ID: covidwho-750361

ABSTRACT

ABSTRACT

Hydroxychloroquine has been used worldwide as a first-line treatment for patients hospitalized with COVID-19. Little is known about COVID-19 and its effects on patients with congenital red blood cell disorders. We report a case of haemolytic anaemia in a 32-year-old patient and a fortuitous highlighting of G6PD deficiency. We reviewed the literature to assess the risk of hydroxychloroquine use in this context. LEARNING POINTS A rapid drop in haemoglobin in COVID-19 patients should alert physicians to test for haemolytic anaemia and enzymopathies.Our review of the literature shows that use of hydroxychloroquine is safe in G6PD-deficient patients.

Keywords

COVID-19; G6PD deficiency; Haemolytic anaemia; SARS-CoV-2

Fulltext

XML

PubMed Links

Search on Google

Full text: Available Collection: International databases Database: MEDLINE Type of study: Prognostic study Language: English Journal: Eur J Case Rep Intern Med Year: 2020 Document Type: Article Affiliation country: 2020_001875

Similar

MEDLINE

LILACS

LIS

Fulltext

XML

PubMed Links

Search on Google